Literature DB >> 31798376

Supportive Care - Different Agents and Strategies in the Combat against Toxicities in Anticancer Therapy.

Karin Jordan1, Juliane Brandt1.   

Abstract

Entities:  

Year:  2019        PMID： 31798376      PMCID： PMC6886111          DOI： 10.1159/000499896

Source DB:  PubMed          Journal:  Breast Care (Basel)        ISSN： 1661-3791            Impact factor:   2.860


× No keyword cloud information.
  6 in total

1.  Overall survival and risk of second malignancies with cancer chemotherapy and G-CSF support.

Authors:  G H Lyman; L Yau; R Nakov; A Krendyukov
Journal:  Ann Oncol       Date:  2018-09-01       Impact factor: 32.976

2.  European Society for Medical Oncology (ESMO) position paper on supportive and palliative care.

Authors:  K Jordan; M Aapro; S Kaasa; C I Ripamonti; F Scotté; F Strasser; A Young; E Bruera; J Herrstedt; D Keefe; B Laird; D Walsh; J Y Douillard; A Cervantes
Journal:  Ann Oncol       Date:  2018-01-01       Impact factor: 32.976

3.  The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study.

Authors:  Richard S Finn; John P Crown; Istvan Lang; Katalin Boer; Igor M Bondarenko; Sergey O Kulyk; Johannes Ettl; Ravindranath Patel; Tamas Pinter; Marcus Schmidt; Yaroslav Shparyk; Anu R Thummala; Nataliya L Voytko; Camilla Fowst; Xin Huang; Sindy T Kim; Sophia Randolph; Dennis J Slamon
Journal:  Lancet Oncol       Date:  2014-12-16       Impact factor: 41.316

4.  Unanticipated toxicities from anticancer therapies: survivors' perspectives.

Authors:  Mona Gandhi; Karen Oishi; Beth Zubal; Mario E Lacouture
Journal:  Support Care Cancer       Date:  2009-12-03       Impact factor: 3.603

Review 5.  Supportive Treatments for Patients with Cancer.

Authors:  Karin Jordan; Petra Feyer; Ulrike Höller; Hartmut Link; Bernhard Wörmann; Franziska Jahn
Journal:  Dtsch Arztebl Int       Date:  2017-07-10       Impact factor: 5.594

6.  A randomized phase III study evaluating the efficacy of single-dose NEPA, a fixed antiemetic combination of netupitant and palonosetron, versus an aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy (HEC).

Authors:  L Zhang; S Lu; J Feng; A Dechaphunkul; J Chang; D Wang; S Chessari; C Lanzarotti; K Jordan; M Aapro
Journal:  Ann Oncol       Date:  2018-02-01       Impact factor: 32.976
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.